Blueprint, Now With 60 Startups, Debuts Latest Healthtech Crop

The numbers are quickly growing for Blueprint Health.

Some four years into its existence, Blueprint—the New York City-based healthtech startup incubator—has now helped launch 60 companies. That includes the seven that debuted on Friday at the latest Blueprint demo day at the City Winery in SoHo. The new group, toting digital health solutions for insurance brokers, dieticians, and other health providers, is Blueprint’s seventh graduating class.

So what type of progress are all these companies making?

Executive director Jean-Luc Neptune—an entrepreneur and the former senior vice president of Health 2.0 who joined Blueprint in December—said that 85 percent of Blueprint’s startups are still in business, and 80 percent of them are generating revenue. Neptune wouldn’t specify exactly how many of them are profitable; he told Xconomy that “a number” of them “are in the range of being profitable,” while adding that “most of them are focused on growth and not profitability at this point.”

One example is Touch Surgery, the developer of a mobile surgical simulation app; the company, part of Blueprint’s third class, now has 50 employees and over 300,000 users. Another member of that class, iMedicare, a startup with an online dashboard that pharmacies can use to help patients choose Medicare plans, is up to 30 or so employees, Neptune said.

He added another factoid about Blueprint’s progress: the value of Blueprint’s equity stakes in the companies it’s backed is three and a half times the capital that it has invested in those startups. Blueprint doesn’t have any big exits under its belt as of yet (like an acquisition of one of its seedling companies), but nonetheless Neptune noted the packed house at the City Winery and the increasing number of local entrepreneurs trying to get into Blueprint’s program and said: “I think that’s a sign that what we’re doing is real.”

Blueprint takes a 6 percent equity stake in the startups it helps form; in return, companies get $20,000 in cash, a home base in Blueprint’s SoHo loft, and another $70,000 in legal, human resources, and other costs. Blueprint—a member of the Techstars Network group of incubators—then takes its accepted applicants through a three-month boot camp culminating in a demo day pitching to angel investors and venture capitalists.

Blueprint is one of a group of healthtech startup creators in New York City, including StartUp Health (which has launched over 90 companies, three of which have been acquired), New York Digital Health Accelerator, and Welltech Funding. The Big Apple has seen a number of incubators pop up in the broader healthcare sector over the past few years. Biotech now has two, for instance, in Manhattan’s Harlem Biospace and BioBAT at the Brooklyn Army Terminal; there are other efforts underway as well. They’re all part of a life sciences scene that has been mobilizing in ways that it historically hasn’t.

As for Blueprint’s latest crew, here’s a brief summary of their ideas, and the seed funds they’re raising, from last Friday’s festivities:

GlucoIQ: Diabetes patients typically have to log their blood glucose levels in notebooks to report back to a doctor, says GlucoIQ CEO Adithya Ganesh. His startup aims to digitize the process. Each patient gets a glucometer that transmits data in real-time to a software platform managed by GlucoIQ. Nurses staffed by the startup call patients to review the data and handle a messaging service. GlucoIQ gets a cut of

Author: Ben Fidler

Ben is former Xconomy Deputy Editor, Biotechnology. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.